Summary & Overview
HCPCS G0682: Application of Non-Sheet Human Cell/Tissue Skin Substitute
HCPCS Level II code G0682 denotes application of a regulated human cell, tissue, or cellular and tissue-based product (HCT/P) in non-sheet form used as a skin substitute for wounds up to 100 square centimeters, with add-on units for each additional 25 square centimeters. This code captures use of products cleared via PMA, 510(k), or regulated under section 361, reflecting growing use of advanced biologic therapies for complex or non-healing wounds. Nationally, such codes matter for tracking utilization of high-cost biologic wound treatments and for aligning coverage and coding practices across payers.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will learn how G0682 is defined clinically and administratively, which settings typically deliver the service, and where to look for benchmarking and policy considerations. The publication summarizes billing context, relevant service lines, and common operational considerations for providers and billing teams. It also flags areas where payer coverage policies and coding guidance commonly influence claim acceptance and reimbursement. Data not available in the input for specific modifiers, taxonomies, ICD-10 pairings, and payer-specific payment rates.
Billing Code Overview
HCPCS Level II code G0682 describes the application of a premarket approval (PMA), 510(k), or 361 human cells, tissues, or cellular and tissue-based product (HCT/P) in a non-sheet form used as a skin substitute for wound coverage. The code applies to treatment of a wound surface area up to 100 square centimeters, with additional units billed for each additional 25 square centimeters or part thereof.
Service type: Skin substitute application for wound care using regulated human cell or tissue products
Typical site of service: Outpatient wound care settings, including hospital outpatient departments, ambulatory surgical centers, and specialized wound clinics where advanced biologic dressing products are applied.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with a non-healing full-thickness diabetic foot ulcer measuring 85 square centimeters presents to a wound care clinic after four weeks of standard care without progression. The multidisciplinary team includes a podiatrist and a wound care nurse. After debridement, wound measurement and photographic documentation, the clinician determines the wound is appropriate for a cellular and tissue-based product (non-sheet form skin substitute) cleared by PMA/510(k) or regulated under section 361. The product is applied to the wound bed in clinic under sterile technique. The initial application is billed with G0682 for the up-to-100 sq cm primary area. If the wound were larger than 100 sq cm or additional graft material beyond the primary 100 sq cm is needed, additional units billed using the additive unit increment described in the code are appended. Typical workflow steps: wound assessment and documentation, debridement, hemostasis, product selection and thawing/preparation, application of the hct/p non-sheet skin substitute, dressing placement, patient instructions, and scheduled follow-up for graft take assessment and potential repeat application if clinically indicated. Typical sites of service are outpatient wound care clinics, physician offices (podiatry, dermatology, plastic surgery), and ambulatory surgery centers when applicable. Payors involved may include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare depending on patient coverage.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|